<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/10/shutterstock_1859230510-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/10/shutterstock_1859230510-430x241.jpg"/></p>
<p>这些技术旨在恢复组织的功能并使体细胞年轻化。图片来源：Marian Weyo/Shutterstock.com。</p>
<p>生物遗传学公司 Klotho Neurosciences 已宣布计划收购 Turn Biotechnologies 的资产，这标志着在长寿治疗开发方面的一次重要举措。</p>
<p>Turn Biotechnologies 专注于诱导多能干细胞（iPSCs）和细胞重编程。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>LOA 和 PTSR 模型 - 单克隆抗体结合物 3 针对 Egfr...</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>LOA 和 PTSR 模型 - CYNK-101</h4>
<h5>数据洞察</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现高效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
<p>了解更多</p>
<p>Klotho 已签署意向书（LOI）。</p>
<p>现金和股票交易取决于尽职调查的完成、最终协议的签署以及典型的成交条件的满足。</p>
<p>根据 LOI 的条款，Klotho 将获得对 Turn 的年龄表观遗传重编程（ERA）平台和 eTurna RNA 递送系统的控制权。</p>
<p>该平台在美国斯坦福大学开发，并由该机构独家许可，ERA 平台利用 eTurna 系统。</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 战略情报</p>
<h1>美国关税正在变化 - 你会反应还是预见？</h1>
<p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
<p>由 GlobalData 提供</p>
<p>了解更多关于战略情报</p>
<p>这些技术旨在恢复组织的功能并使体细胞年轻化，可能导致眼科、皮肤科、骨关节炎、肌肉健康、免疫学和肌萎缩侧索硬化症（ALS）等多种再生疗法。</p>
<p>交易的一个关键方面是 Klotho 收购与一家韩国制药公司的外许可和联合开发合作伙伴关系，该合作伙伴关系的价值可能高达 3 亿美元。</p>
<p>这一合作展示了市场对 Turn 平台的商业兴趣，强调了其技术的广泛潜力。</p>
<p>在预计完成收购后，Klotho 计划进行品牌重塑，以更好地代表其更广泛的使命和治疗能力。</p>
<p>该公司还计划在交易完成后欢迎 Turn Biotechnologies 的管理和研发部门的关键人员。</p>
<p>Klotho Neurosciences 首席执行官 Dr Joseph Sinkule 表示：“这份 LOI 标志着 Klotho 的一个变革性步骤。Klotho 基因通常被称为 ‘抗衰老基因’，首次因其延长动物模型寿命和保护神经退行性疾病的能力而被识别。我们的公司成立的目的是将这一科学转化为对抗与年龄相关的衰退的疗法。”</p>
<p>“通过增加 Turn 的 ERA 技术——该技术利用六种 RNA 分子，包括四种可以重置细胞年龄的 Yamanaka 转录因子——以及 eTurna RNA 脂质纳米颗粒（LNP）递送平台，我们正在超越单一的 Klotho 基因，构建一个强大的细胞年轻化系统。”</p>
<h2>制药技术卓越奖 - 参赛的好处</h2>
<p>获得你应得的认可！制药技术卓越奖 庆祝创新、领导力和影响力。通过参赛，你展示了你的成就，提高了你的行业形象，并将自己置于推动制药进步的顶尖领导者之中。不要错过脱颖而出的机会——今天就提交你的参赛作品！</p>
<p>立即提名</p>

TURN

<p>Klotho Neurosciences 计划收购 Turn Biotechnologies 的资产，重点关注组织修复和细胞复兴技术。该交易需依赖尽职调查和最终协议，包括 Turn 的年龄表观遗传重编程（ERA）平台和 eTurna RNA 递送系统。这项收购可能会与一家韩国制药公司达成价值高达 3 亿美元的合作。Klotho 旨在收购后进行品牌重塑，并整合 Turn 的关键人员，以增强其在长寿治疗领域的使命</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/10/shutterstock_1859230510-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/10/shutterstock_1859230510-430x241.jpg"/></p>
<p>The technologies are intended to restore the function of tissues and rejuvenate somatic cells. Credit: Marian Weyo/Shutterstock.com.</p>
<div class="lb-trans"><p>这些技术旨在恢复组织的功能并使体细胞年轻化。图片来源：Marian Weyo/Shutterstock.com。</p>
</div><p>Biogenetics company Klotho Neurosciences has announced plans to acquire assets from Turn Biotechnologies, marking a move in the development of longevity therapeutics.</p>
<div class="lb-trans"><p>生物遗传学公司 Klotho Neurosciences 已宣布计划收购 Turn Biotechnologies 的资产，这标志着在长寿治疗开发方面的一次重要举措。</p>
</div><p>Turn Biotechnologies is focused on induced pluripotent stem cells (iPSCs) and cellular reprogramming.</p>
<div class="lb-trans"><p>Turn Biotechnologies 专注于诱导多能干细胞（iPSCs）和细胞重编程。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>LOA and PTSR Model - Monoclonal Antibody Conjugate 3 To Target Egfr...</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - 单克隆抗体结合物 3 针对 Egfr...</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>LOA and PTSR Model - CYNK-101</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - CYNK-101</h4>
</div><h5>Data Insights</h5>
<div class="lb-trans"><h5>数据洞察</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现高效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>Klotho has signed a letter of intent (LOI) in this regard.</p>
<div class="lb-trans"><p>Klotho 已签署意向书（LOI）。</p>
</div><p>The cash and stock deal is contingent upon the completion of due diligence, the execution of a definitive agreement and fulfilment of typical closing conditions.</p>
<div class="lb-trans"><p>现金和股票交易取决于尽职调查的完成、最终协议的签署以及典型的成交条件的满足。</p>
</div><p>Under the LOI’s terms, Klotho would gain control of Turn’s Epigenetic Reprogramming of Age (ERA) platform and the eTurna RNA delivery system.</p>
<div class="lb-trans"><p>根据 LOI 的条款，Klotho 将获得对 Turn 的年龄表观遗传重编程（ERA）平台和 eTurna RNA 递送系统的控制权。</p>
</div><p>Developed at Stanford University in the US, and exclusively licensed by the institution, the ERA platform leverages the eTurna system.</p>
<div class="lb-trans"><p>该平台在美国斯坦福大学开发，并由该机构独家许可，ERA 平台利用 eTurna 系统。</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 战略情报</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美国关税正在变化 - 你会反应还是预见？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>由 GlobalData 提供</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>了解更多关于战略情报</p>
</div><p>These technologies are intended for restoring the function of tissues and rejuvenating somatic cells, potentially leading to a variety of regenerative therapies in ophthalmology, dermatology, osteoarthritis, muscle health, immunology and amyotrophic lateral sclerosis (ALS).</p>
<div class="lb-trans"><p>这些技术旨在恢复组织的功能并使体细胞年轻化，可能导致眼科、皮肤科、骨关节炎、肌肉健康、免疫学和肌萎缩侧索硬化症（ALS）等多种再生疗法。</p>
</div><p>A key aspect of the transaction is Klotho’s acquisition of an out-licensing and joint development partnership with a South Korean pharmaceutical company, which could be worth up to $300m.</p>
<div class="lb-trans"><p>交易的一个关键方面是 Klotho 收购与一家韩国制药公司的外许可和联合开发合作伙伴关系，该合作伙伴关系的价值可能高达 3 亿美元。</p>
</div><p>This collaboration demonstrates the commercial interest in Turn’s platform, underscoring the wide-ranging potential of its technology.</p>
<div class="lb-trans"><p>这一合作展示了市场对 Turn 平台的商业兴趣，强调了其技术的广泛潜力。</p>
</div><p>Following the anticipated completion of the acquisition, Klotho plans to undergo rebranding to better represent its wider mission and therapeutic capabilities.</p>
<div class="lb-trans"><p>在预计完成收购后，Klotho 计划进行品牌重塑，以更好地代表其更广泛的使命和治疗能力。</p>
</div><p>The company also plans to welcome key Turn Biotechnologies personnel from their management and research and development departments after the transaction is finalised.</p>
<div class="lb-trans"><p>该公司还计划在交易完成后欢迎 Turn Biotechnologies 的管理和研发部门的关键人员。</p>
</div><p>Klotho Neurosciences CEO Dr Joseph Sinkule stated: “This LOI marks a transformative step for Klotho. The Klotho gene is often referred to as the ‘anti-aging gene,’ first identified for its ability to extend lifespan in animal models and protect against neurodegenerative diseases. Our company was founded on translating that science into therapies that combat age-related decline.</p>
<div class="lb-trans"><p>Klotho Neurosciences 首席执行官 Dr Joseph Sinkule 表示：“这份 LOI 标志着 Klotho 的一个变革性步骤。Klotho 基因通常被称为 ‘抗衰老基因’，首次因其延长动物模型寿命和保护神经退行性疾病的能力而被识别。我们的公司成立的目的是将这一科学转化为对抗与年龄相关的衰退的疗法。”</p>
</div><p>“By adding Turn’s ERA technology — which leverages six RNA molecules, including four of the Yamanaka transcription factors that can reset cellular age — together with the eTurna RNA lipid nanoparticle (LNP) delivery platform, we are expanding beyond a single Klotho gene into a powerful system of cellular rejuvenation.”</p>
<div class="lb-trans"><p>“通过增加 Turn 的 ERA 技术——该技术利用六种 RNA 分子，包括四种可以重置细胞年龄的 Yamanaka 转录因子——以及 eTurna RNA 脂质纳米颗粒（LNP）递送平台，我们正在超越单一的 Klotho 基因，构建一个强大的细胞年轻化系统。”</p>
</div><h2>Pharmaceutical Technology Excellence Awards - The Benefits of Entering</h2>
<div class="lb-trans"><h2>制药技术卓越奖 - 参赛的好处</h2>
</div><p>Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!</p>
<div class="lb-trans"><p>获得你应得的认可！制药技术卓越奖 庆祝创新、领导力和影响力。通过参赛，你展示了你的成就，提高了你的行业形象，并将自己置于推动制药进步的顶尖领导者之中。不要错过脱颖而出的机会——今天就提交你的参赛作品！</p>
</div><p>Nominate Now</p>
<div class="lb-trans"><p>立即提名</p>
</div>

Klotho 将收购 Turn Biotechnologies 的资产